Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation

Sponsor

Swiss Federal Institute of Technology (Other)

Overall Status

Completed

CT.gov ID

NCT02745925

Collaborator

University of Monterrey, Mexico (Other)

Enrollment

Location

Arms

Actual Duration (Months)

1.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The main iron regulatory protein in the human metabolism is hepcidin. In normal weight, healthy subjects, hepcidin is regulated through the iron status of the body: low iron status results in low hepcidin concentrations, which facilitates dietary iron absorption. In obesity, which is an inflammatory state, hepcidin concentrations are increased and iron absorption is reduced despite low iron stores, leading to iron deficiency over time. Whether lowering the chronic low-grade inflammation during a limited treatment period and thereby lowering hepcidin concentration can improve iron absorption is uncertain.

Condition or Disease	Intervention/Treatment	Phase
Obesity	Drug: Ibuprofen	N/A

Detailed Description

In states of high hepcidin concentration, intestinal iron absorption (through enterocytes) and recycling of iron (through macrophages) is reduced. The extent to which non-heme iron is absorbed from the diet is influenced by the composition of the diet. Ascorbic acid is a potent enhancer of non-heme iron absorption. It's mechanism of action is luminal reduction of dietary ferric iron (Fe3+) to more soluble ferrous iron (Fe2+). A study in the inestigator's laboratory showed that the enhancing effect of ascorbic acid on non-heme iron absorption is reduced in overweight and obese individuals. Possible explanations for this fact are the different sites of action of ascorbic acid and serum hepcidin on the enterocytes in dietary iron absorption. Increased hepcidin reduces iron efflux into the circulation at the basolateral membrane of the enterocyte. Therefore the improved iron transport into enterocytes through ascorbic acid at the luminal side (via the divalent metal transporter (DMT)-1), by reducing Fe3+ to Fe2+ seems to be less successful. To improve iron absorption in obese subjects, an intervention at the basolateral membrane of the enterocyte would be needed.

Study Design

Study Type:

Interventional

Actual Enrollment :

40 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Basic Science

Official Title:

Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation

Actual Study Start Date :

Apr 1, 2016

Actual Primary Completion Date :

Dec 1, 2018

Actual Study Completion Date :

Dec 1, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: normal-weight normal-weight women	Drug: Ibuprofen
Experimental: obesity obese women	Drug: Ibuprofen

Arm

Intervention/Treatment

Experimental: normal-weight

normal-weight women

Drug: Ibuprofen

Experimental: obesity

obese women

Drug: Ibuprofen

Outcome Measures

Primary Outcome Measures

Fractional iron absorption [Days 15 and 45]
The fractional iron absorption from four test meals will be calculated based on the shift of the iron isotopic ratios in the collected blood samples 14 days after administration of the isotopically labeled meals. Calculation of fractional iron absorption will take into account the principles of isotope dilution and the fact that iron isotopic labels are not mono-isotopic. The investigators assumed iron incorporation into erythrocytes to be constant. Blood volume, needed for the calculation of fractional iron absorption will be estimated based on available data on blood volume estimations in obese women.

Secondary Outcome Measures

Plasma ferritin [Days 1, 15, 30, 45]
Hemoglobin [Days 1, 15, 30, 45]
Transferrin receptor [Days 1, 15, 30, 45]
Hepcidin [Days 1, 15, 30, 45]
c-reactive protein [Days 1, 15, 30, 45]
interleukin-6 [Days 1, 15, 30, 45]
alpha-1-acid-glycoprotein [Days 1, 15, 30, 45]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 45 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

normal-weight (BMI18.5-24.9kg/m2) or obesity (BMI 29-40kg/m2)
pre-menopausal
no chronic illness and no significant medical conditions that could influence iron or inflammatory status other than obesity
no-smoking

Exclusion Criteria:

Diagnosed chronic disease or gastrointestinal disorders
Metabolic disorders (e.g. diabetes)
Regular use of medication (except oral contraceptives)
Subject on a weight loss diet or planning to start a weight loss diet during the duration of the study
Pregnancy or lactation